Aprea Therapeutics (APRE) News Today $4.05 +0.20 (+5.19%) Closing price 04:00 PM EasternExtended Trading$4.12 +0.07 (+1.73%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Aprea Therapeutics Discloses Unaudited Financials and Updates Corporate PresentationAprea Therapeutics, Inc. recently released an updated corporate presentation, alongside disclosing financial information as of December 31, 2024. The company shared tJanuary 21 at 2:05 AM | americanbankingnews.comAprea Therapeutics' (APRE) "Buy" Rating Reiterated at HC WainwrightJanuary 18 at 1:32 AM | americanbankingnews.comStrategic Advancements and Financial Stability Drive Buy Rating for Aprea TherapeuticsJanuary 16, 2025 | markets.businessinsider.comH.C. Wainwright sets target on Aprea stock, Buy rating on clinical updateJanuary 16, 2025 | msn.comPromising Clinical Advances Drive Buy Rating for Aprea TherapeuticsDecember 17, 2024 | markets.businessinsider.comAprea Therapeutics’ Promising ATRN-119: A Buy Rating Amid Optimized Dosing and Safety AdvancementsDecember 13, 2024 | markets.businessinsider.comAprea Therapeutics Updates ABOYA-119 Trial with Twice Daily DosingDecember 13, 2024 | msn.comAprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path ForwardDecember 11, 2024 | globenewswire.comAprea Therapeutics: Buy Rating Driven by Clinical Progress and Financial StabilityNovember 18, 2024 | markets.businessinsider.comAprea Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 11, 2024 | finance.yahoo.comBuy Recommendation for Aprea Therapeutics Based on Promising Clinical Progress and Strategic Financial PositioningNovember 9, 2024 | markets.businessinsider.comAprea Therapeutics Reports Q3 Financials and Advances in Clinical TrialsNovember 9, 2024 | msn.comAprea Therapeutics reports Q3 EPS (64c) vs (86c) last yearNovember 8, 2024 | markets.businessinsider.comAprea Therapeutics Presents Promising Safety Data for WEE1 Inhibitor at International SymposiumOctober 26, 2024 | msn.comAprea Therapeutics, Inc. (NASDAQ:APRE) Director Sells $29,595.96 in StockOctober 26, 2024 | insidertrades.comPromising Safety and Financial Strength Propel Buy Rating for Aprea TherapeuticsOctober 25, 2024 | markets.businessinsider.comInsider Spends US$132k Buying More Shares In Aprea TherapeuticsOctober 23, 2024 | finance.yahoo.comAprea Therapeutics presents preliminary results on APR-1051October 23, 2024 | markets.businessinsider.comOptimistic Buy Recommendation for Aprea Therapeutics: Promising Developments in WEE1 Kinase InhibitorOctober 23, 2024 | markets.businessinsider.comAprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and TherapeuticsOctober 23, 2024 | globenewswire.comAprea Therapeutics, Inc. (NASDAQ:APRE) Director Buys $131,700.00 in StockOctober 18, 2024 | insidertrades.comAprea Therapeutics to Showcase Expertise at Maxim Healthcare Virtual SummitOctober 16, 2024 | msn.comInsider Buying: Aprea Therapeutics, Inc. (NASDAQ:APRE) Director Buys 10,000 Shares of StockOctober 16, 2024 | insidertrades.comAprea Therapeutics to Present at Maxim 2024 Healthcare Virtual SummitOctober 14, 2024 | globenewswire.comAprea Therapeutics to Showcase Oncology Advances at Barcelona SymposiumOctober 12, 2024 | msn.comAprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and TherapeuticsOctober 10, 2024 | globenewswire.comAprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical DevelopmentOctober 9, 2024 | globenewswire.comAprea Therapeutics to Present at Lytham Partners Fall Investor ConferenceSeptember 26, 2024 | msn.comAprea Therapeutics to Present at the Life Sciences Investor Forum on September 19September 12, 2024 | finance.yahoo.comDoylestown Cancer Pharma Moves Closer to Starting Clinical Testing on Its 3rd Experimental Cancer TreatmentSeptember 10, 2024 | msn.comUPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment ConferenceSeptember 9, 2024 | globenewswire.comAprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment ConferenceSeptember 9, 2024 | globenewswire.comAprea Therapeutics to Present at H.C. Wainwright Investment ConferenceAugust 29, 2024 | msn.comAprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment ConferenceAugust 28, 2024 | globenewswire.comActor John Aprea Had a Long Career in Hollywood: A Look Back at His Life After His Death at Age 83August 19, 2024 | yahoo.comJohn Aprea, The ‘Godfather II’ and ‘Full House’ Actor, Dies At 83August 19, 2024 | forbes.comJohn Aprea, Another World And Knots Landing Star, Died At 83August 19, 2024 | yahoo.comJohn Aprea Dies: ‘The Godfather Part II’ & ‘Full House’ Actor Was 83August 18, 2024 | msn.comJohn Aprea, ‘Godfather Part II’ and ‘Full House’ Actor, Dies at 83August 18, 2024 | msn.comJohn Aprea, ‘The Godfather Part II’ Actor, Dies at 83August 18, 2024 | msn.comJohn Aprea, Actor in ‘The Godfather Part II’ and ‘Full House,’ Dies at 83August 18, 2024 | msn.comJohn Aprea Dies: ‘Another World’ & ‘Full House’ Star Was 83August 18, 2024 | msn.comJohn Aprea, "The Godfather Part II" and "Full House" actor, dies at 83August 18, 2024 | msn.comAprea Therapeutics Reports Second Quarter 2024 Financial Results and Progress in Clinical TrialsAugust 14, 2024 | msn.comBuy Rating Justified by Aprea Therapeutics’ Financial Health and Innovative Clinical TrialsAugust 13, 2024 | markets.businessinsider.comAprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 12, 2024 | globenewswire.comAprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024June 21, 2024 | globenewswire.comAprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051June 17, 2024 | globenewswire.comAprea Therapeutics Advances Cancer Treatment Trial to Higher Dose LevelMay 29, 2024 | msn.comAprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical TrialMay 28, 2024 | globenewswire.com Get Aprea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter. Email Address APRE Media Mentions By Week APRE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APRE News Sentiment▼0.200.57▲Average Medical News Sentiment APRE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APRE Articles This Week▼51▲APRE Articles Average Week Get Aprea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KPTI News Today CUE News Today JSPR News Today CLLS News Today ADAG News Today VTGN News Today BLUE News Today SKYE News Today THTX News Today ASRT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APRE) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aprea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
